Arrowstreet Capital, Limited Partnership Entrada Therapeutics, Inc. Transaction History
Arrowstreet Capital, Limited Partnership
- $114 Billion
- Q2 2024
A detailed history of Arrowstreet Capital, Limited Partnership transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Arrowstreet Capital, Limited Partnership holds 14,307 shares of TRDA stock, worth $235,350. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,307
Previous 14,307
-0.0%
Holding current value
$235,350
Previous $203,000
0.49%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding TRDA
# of Institutions
84Shares Held
27.7MCall Options Held
100Put Options Held
0-
Baker Bros. Advisors LP New York, NY4.87MShares$80 Million0.92% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.43MShares$72.8 Million34.63% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$72.5 Million29.39% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.13MShares$51.6 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.69MShares$27.9 Million0.0% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $516M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...